- Home
- ARDT vs VCEL Comparison
ARDT vs VCEL Comparison
Compare ARDT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDT
- VCEL
- Stock Information
- Founded
- ARDT 2001
- VCEL 1989
- Country
- ARDT United States
- VCEL United States
- Employees
- ARDT N/A
- VCEL N/A
- Industry
- ARDT
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARDT
- VCEL Health Care
- Exchange
- ARDT NYSE
- VCEL Nasdaq
- Market Cap
- ARDT 2.1B
- VCEL 2.1B
- IPO Year
- ARDT 2024
- VCEL 1997
- Fundamental
- Price
- ARDT $13.42
- VCEL $41.46
- Analyst Decision
- ARDT Buy
- VCEL Strong Buy
- Analyst Count
- ARDT 13
- VCEL 8
- Target Price
- ARDT $20.77
- VCEL $62.00
- AVG Volume (30 Days)
- ARDT 307.1K
- VCEL 450.2K
- Earning Date
- ARDT 08-13-2025
- VCEL 07-31-2025
- Dividend Yield
- ARDT N/A
- VCEL N/A
- EPS Growth
- ARDT 935.52
- VCEL 521.85
- EPS
- ARDT 1.64
- VCEL 0.05
- Revenue
- ARDT $6,024,260,000.00
- VCEL $238,541,000.00
- Revenue This Year
- ARDT $8.25
- VCEL $23.03
- Revenue Next Year
- ARDT $5.56
- VCEL $24.52
- P/E Ratio
- ARDT $8.22
- VCEL $702.91
- Revenue Growth
- ARDT 8.91
- VCEL 14.80
- 52 Week Low
- ARDT $11.31
- VCEL $37.39
- 52 Week High
- ARDT $20.72
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- ARDT N/A
- VCEL 46.36
- Support Level
- ARDT N/A
- VCEL $40.53
- Resistance Level
- ARDT N/A
- VCEL $43.57
- Average True Range (ATR)
- ARDT 0.00
- VCEL 1.70
- MACD
- ARDT 0.00
- VCEL -0.12
- Stochastic Oscillator
- ARDT 0.00
- VCEL 34.04
About ARDT ARDENT HEALTH PARTNERS INC
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.